ONC Stock Overview
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
BeOne Medicines Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$246.68 |
| 52 Week High | US$287.88 |
| 52 Week Low | US$141.31 |
| Beta | 0.35 |
| 1 Month Change | -1.24% |
| 3 Month Change | -9.24% |
| 1 Year Change | 59.92% |
| 3 Year Change | 77.71% |
| 5 Year Change | 43.83% |
| Change since IPO | 771.05% |
Recent News & Updates
Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
May 15
US Facility And Phase III Trials Will Expand Markets
Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies.Recent updates
Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
May 15US Facility And Phase III Trials Will Expand Markets
Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies.Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?
Apr 23BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Feb 28BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Feb 06Is BeiGene (NASDAQ:ONC) A Risky Investment?
Jan 14BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
Dec 01BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
Nov 06BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
May 30BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08Shareholder Returns
| ONC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | 0.4% | 0.8% |
| 1Y | 59.9% | -9.6% | 11.5% |
Return vs Industry: ONC exceeded the US Biotechs industry which returned -9.6% over the past year.
Return vs Market: ONC exceeded the US Market which returned 11.5% over the past year.
Price Volatility
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: ONC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ONC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 11,000 | John Oyler | beonemedicines.com |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
BeOne Medicines Ltd. Fundamentals Summary
| ONC fundamental statistics | |
|---|---|
| Market cap | US$28.50b |
| Earnings (TTM) | -US$392.37m |
| Revenue (TTM) | US$4.18b |
Is ONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONC income statement (TTM) | |
|---|---|
| Revenue | US$4.18b |
| Cost of Revenue | US$634.16m |
| Gross Profit | US$3.54b |
| Other Expenses | US$3.93b |
| Earnings | -US$392.37m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.31 |
| Gross Margin | 84.81% |
| Net Profit Margin | -9.40% |
| Debt/Equity Ratio | 26.4% |
How did ONC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 03:46 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BeOne Medicines Ltd. is covered by 65 analysts. 34 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Michael Meng | BOCI Research Ltd. |
| Yonglin Yan | BOCI Research Ltd. |